NCT00251394已完成2 期
A Phase 2, Open-Label Study of the Efficacy, Safety, and Tolerability of Dynavax's Immunostimulatory Phosphorothiolate Oligodeoxyribonucleotide, 1018 ISS, Following Rituxan (Rituximab) Treatment in Patients With CD20+, B-Cell Follicular Non-Hodgkin's Lymphoma.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 6
- 主要终点
- To determine the proportion of patients who are alive and without disease progression 1 year after initiating Rituxan plus 1018 ISS therapy.
研究概览
简要总结
The main purpose of this study is to determine the effects (good and bad) and the safety of Dynavax's immunostimulatory phosphorothiolate oligodeoxyribonucleotide (1018 ISS) given in combination with Rituxan on patients with B-cell follicular non-Hodgkin's lymphoma. This research is being done because recurrent follicular non-Hodgkin's lymphoma is not curable with standard chemotherapy or antibody treatments. 1018 ISS is an experimental compound that consists of short pieces of DNA that stimulate the immune system. It is hoped that 1018 ISS may improve the ability of Rituxan to kill cancer cells.
详细描述
- Patients will receive four weekly infusions of Rituxan which is standard treatment for B-cell non-Hodgkin's lymphoma. Approximately 30 to 60 minutes after the second, third and fourth infusions of Rituxan, the patient will receive up to 3 injections of 1018 ISS under the skin. The number of injections will depend upon the patients weight. One week after the last Rituxan infusion the patient will receive a fourth and final injection of 1018 ISS.
- After completion of the 5-week treatment period, a physical examination and blood work will be performed. The patient will also be examined to see if the tumor has gotten smaller, bigger, or stayed the same size and in the same places by either CT scan or MRI. A bone marrow aspiration and biopsy will be done to examine any changes in bone marrow cells.
- The following tests will be performed to determine whether or not a patient is eligible to participate in this clinical study: Bone marrow aspiration and biopsy; lymph node biopsy; skin biopsy; standard x-ray tests (x-rays, CT scans, MRI, ultrasounds, and/or radioactive drug scans); and blood work.
- While receiving treatment patients will have the following procedures done; Physical examination once a week for 4 weeks, blood testing for any changes in the blood, blood chemistry and other blood components. Patients will also be requested to keep a diary between each study visit to record any health changes or any over-the-counter medication or herbal preparation they may have taken.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Pathological evidence of CD20+, B-cell follicular non-Hodgkin's lymphoma
- •Received at least one previous chemotherapy regimen for lymphoma
- •Hemoglobin > 8.5 g/dl
- •WBC > 2,000/mm3
- •ANC > 1,000/mm3
- •Platelet count > 75,000/mm3
- •ECOG performance status of less than or equal to 2
- •Life expectancy of greater than 4 months
- •Women and men of childbearing potential must be willing to use highly effective methods of birth control for duration of time on the study
排除标准
- •Pregnant of lactating women
- •Treatment with chemotherapy, including systemic steroids, or radiation therapy within 30 days
- •Current use of systemic or inhaled steroids
- •Treatment with radioimmunotherapy, autologous stem cell transplantation, or fludarabine within 6 months
- •Disease progression within 6 months of any previous rituximab therapy
- •History of allogenic transplantation, including nonmyeloablative transplantation
- •Unstable angina, symptomatic cardiac arrhythmia or clinical heart failure
- •Severe pulmonary disease, symptomatic pleural effusions, or clinically significant pulmonary symptoms
- •Active infection requiring systemic antibiotic, antiviral, or antifungal therapy
- •Clinically apparent CNS lymphoma
- •Major surgery within 2 weeks
- •Known human anti-murine antibody (HAMA) or human anti-chimeric antibody (HACA) response
- •Known Hepatitis B surface antigen positive
- •History of autoimmune disorder
- •Current therapeutic use of anticoagulants
- •History of coagulopathy
- •Known allergy to any of the components of 1018 ISS or Rituxan
- •Participation in another investigational trial within 30 days
- •Any clinically significant abnormality in screening blood chemistry, hematology, or urinalysis
结局指标
主要结局
To determine the proportion of patients who are alive and without disease progression 1 year after initiating Rituxan plus 1018 ISS therapy.
时间窗: 2 years
次要结局
- To assess the overall response rate following treatment(2 years)
- to determine duration of response and time to progression
- to further define the safety profile of 1018 ISS(2 years)
- to explore the biologic activity of 1018 ISS.(2 years)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT01481194Vejle Hospital35
Unknown
2 期
A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaNCT00925314Cosmo Bioscience20
终止
1 期
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Relapsed/Refractory Peripheral T-cell LymphomaNCT05403450Taiho Oncology, Inc.33
已完成
2 期
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate CancerCastration-resistant Prostate CancerCRPCNCT02012920Innocrin Pharmaceutical200
已完成
2 期
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT00160043Bayer112